Development of a vaccine against SARS-COV-2 using muNS-Mi micro / nanospheres

We have developed and patented a methodology that allows cells of any origin to be programmed to build protein micro (MS) or nanospheres (NS) and introduce any protein of interest into them by tagging them with a tag called IC. These MS function as vaccines in the absence of adjuvants and the integrated proteins fold perfectly, allowing quaternary structures and even enzymatic reactions. In this project we intend to generate microspheres that contain the S1 domain of the S protein or the M or N proteins of SARS COV-2 and to characterize the immune response that they induce when administered intranasally or intramuscularly in a mouse model. The methodology is already developed in the expression systems of baculovirus, mammalian cells and bacteria, and will be adapted to the yeast system for its rapid implementation in human vaccines.